Juhani Junttila

Dr. Juhani Junttila


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2023 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
MOMeri-Maija Ollila
Meri-Maija Ollila
RARiikka K Arffman
Riikka K Arffman
EKElisa Korhonen
Elisa Korhonen
LMLaure Morin-Papunen
Laure Morin-Papunen
SFStephen Franks
Stephen Franks
TPTerhi T Piltonen
Terhi T Piltonen
Objective: Polycystic ovary syndrome (PCOS) is associated with many cardiovascular disease (CVD) risk factors, such as obesity, type 2 diabetes mellitus and hypertension. However, it remains debatable whether the presence of multiple CVD risk factors translates to increased CVD events. Design: A prospective, population-based Northern Finland Birth Cohort 1966. Methods: Individuals with an expected date of birth in 1966 in Northern Finland have been followed from birth. Women in the cohort were classified as having PCOS according to either the National Institute of Health (NIH) criteria (n = 144) or the Rotterdam criteria (n = 386) at age 31, and they were compared to women without any PCOS features. The study population was re-examined at age 46, and the incidence of major adverse cardiovascular events (MACE), including myocardial infarction (MI), stroke, heart failure and cardiovascular mortality, was recorded up to age 53. Results: During the 22-year follow-up, both women with NIH-PCOS and women with Rotterdam-PCOS had a significantly higher risk for cardiovascular events than control women. The BMI-adjusted hazard ratio (HR) for MACE in the Rotterdam-PCOS group and the NIH-PCOS group was 2.33 (1.26-4.30) and 2.47 (1.18-5.17), respectively. The cumulative hazard curves in both diagnostic categories began to diverge at age 35. Regarding the individual CVD endpoints, MI was significantly more prevalent in both women with NIH-PCOS (P = .010) and women with Rotterdam-PCOS (P = .019), when compared to control women. Conclusions: PCOS should be considered a significant risk factor for CVD. Future follow-up will show how the risk of CVD events develops after menopausal age.

1 August 2019 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
JVJuha H. Vähätalo
Juha H. Vähätalo
HHHeikki V. Huikuri
Heikki V. Huikuri
LHLauri T. A. Holmström
Lauri T. A. Holmström
TKTuomas V. Kenttä
Tuomas V. Kenttä
MHM. Anette E. Haukilahti
M. Anette E. Haukilahti
Juhani JunttilaJuhani Junttila
Juhani Junttila
Sudden cardiac death (SCD) is a worldwide major public health burden, accounting for more than 50% of all cardiac deaths and 20% of all deaths in the United States.1,2 Coronary artery disease (CAD) is the most common underlying cause of SCD.3 Often, SCD is the first recognized clinical manifestation of underlying heart disease, and the ability to recognize this specific risk before the event is severely limited.4

8 October 2024 in European Heart Journal
Verified
Journal Article
Open access
PDF file
NPNiels Peek
Niels Peek
GHGerhard Hindricks
Gerhard Hindricks
AAArtur Akbarov
Artur Akbarov
JTJan G P Tijssen
Jan G P Tijssen
DJDavid A Jenkins
David A Jenkins
NDNikolaos Dagres
Nikolaos Dagres
Risk stratification of sudden cardiac death after myocardial infarction and prevention by defibrillator rely on left ventricular ejection fraction (LVEF). Improved risk stratification across the whole LVEF range is required for decision-making on defibrillator implantation. The analysis pooled 20 data sets with 140 204 post-myocardial infarction patients containing information on demographics, medical history, clinical characteristics, biomarkers, electrocardiography, echocardiography, and cardiac magnetic resonance imaging. Separate analyses were performed in patients (i) carrying a primary prevention cardioverter-defibrillator with LVEF ≤ 35% [implantable cardioverter-defibrillator (ICD) patients], (ii) without cardioverter-defibrillator with LVEF ≤ 35% (non-ICD patients ≤ 35%), and (iii) without cardioverter-defibrillator with LVEF > 35% (non-ICD patients >35%). Primary outcome was sudden cardiac death or, in defibrillator carriers, appropriate defibrillator therapy. Using a competing risk framework and systematic internal–external cross-validation, a model using LVEF only, a multivariable flexible parametric survival model, and a multivariable random forest survival model were developed and externally validated. Predictive performance was assessed by random effect meta-analysis. There were 1326 primary outcomes in 7543 ICD patients, 1193 in 25 058 non-ICD patients ≤35%, and 1567 in 107 603 non-ICD patients >35% during mean follow-up of 30.0, 46.5, and 57.6 months, respectively. In these three subgroups, LVEF poorly predicted sudden cardiac death (c-statistics between 0.50 and 0.56). Considering additional parameters did not improve calibration and discrimination, and model generalizability was poor. More accurate risk stratification for sudden cardiac death and identification of low-risk individuals with severely reduced LVEF or of high-risk individuals with preserved LVEF was not feasible, neither using LVEF nor using other predictors. Brief summary of the background, methodology, and results of the PROFID data analysis. ICD patients, patients with left ventricular ejection fraction ≤ 35% who had received a cardioverter-defibrillator implantation for primary prevention of sudden cardiac death; non-ICD patients ≤35%, patients who did not carry a cardioverter-defibrillator and had a left ventricular ejection fraction ≤ 35%; and non-ICD patients >35%, patients who did not carry a cardioverter-defibrillator and had a left ventricular ejection fraction > 35%. Detailed inclusion and exclusion criteria are provided in the text. CMR, cardiac magnetic resonance; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; MI, myocardial infarction.

29 September 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
LHLauri Holmström
Lauri Holmström
SJSamuli Juntunen
Samuli Juntunen
JVJuha Vähätalo
Juha Vähätalo
LPLasse Pakanen
Lasse Pakanen
KKKari Kaikkonen
Kari Kaikkonen
Juhani JunttilaJuhani Junttila
Juhani Junttila
Aims: At least 50% of deaths due to coronary artery disease (CAD) are sudden cardiac deaths (SCDs), but the role of acute plaque complications on the incidence of sudden death in CAD is somewhat unclear. The present study aimed to investigate plaque histology and concomitant myocardial disease in sudden coronary death.Methods and results: The study population is derived from the Fingesture study, which has collected data from 5869 consecutive autopsy-verified SCD victims in Northern Finland (population ≈600 000) between 1998 and 2017. In this substudy, histological examination of culprit lesions was performed in 600 SCD victims whose death was due to CAD. Determination of the cause of death was based on the combination of medical records, police reports, and autopsy data. Plaque histology was classified as either (i) plaque rupture or erosion, (ii) intraplaque haemorrhage, or (iii) stable plaque. The mean age of the study subjects was 64.9 ± 11.2 years, and 82% were male. Twenty-four per cent had plaque rupture or plaque erosion, 24% had an intraplaque haemorrhage, and 52% had a stable plaque. Myocardial hypertrophy was present in 78% and myocardial fibrosis in 93% of victims. The presence of myocardial hypertrophy or fibrosis was not associated with specific plaque histology.Conclusion: Less than half of sudden deaths due to CAD had evidence of acute plaque complication, an observation which is contrary to historical perceptions. The prevalence of concomitant myocardial disease was high and independent of associated plaque morphology.

1 May 2021 in The American Journal of Cardiology
Verified
Journal Article
Open access
JVJuha Vähätalo
Juha Vähätalo
LHLauri Holmström
Lauri Holmström
LPLasse Pakanen
Lasse Pakanen
KKKari Kaikkonen
Kari Kaikkonen
JPJuha Perkiömäki
Juha Perkiömäki
Juhani JunttilaJuhani Junttila
Juhani Junttila
Coronary artery disease (CAD) is the most common cause of sudden cardiac death (SCD). Atherosclerosis increases with age, but also many victims of SCD in young and middle-aged population have CAD at autopsy. The purpose of this study was to determine the characteristics and autopsy findings of SCD due to CAD among victims of SCD under the age of 50. Fingesture is a population-based study consisting of consecutive series of victims of autopsy verified SCD in Northern Finland between the years 1998 to 2017 (n = 5,869). Histological examinations were part of all autopsies and a toxicology investigation was performed if needed. Analyses included information accumulated from death certificates, medical records, autopsy data, standardized questionnaire to the closest family members of the victims of SCD and police reports of the conditions of the death. Overall, 10.4% of all SCDs occurred among victims under the age of 50 years (610 victims). Most common underlying cause of SCD among these younger SCD victims was CAD (43.6%). The prevalence of CAD as the cause of SCD became more common in young SCD victims after the age of 35 years. The mean age of ischemic SCD victims was 44±5 years and most were men (89.5%). Most victims (90.2%) had no clinical diagnosis of CAD, however 33.8% had an autopsy evidence of silent myocardial infarction. SCD occurred during physical activity in 24.1%. Three-vessel disease was detected in 44.4% of the study victims. Cardiac hypertrophy (58.3%) and myocardial fibrosis (82.6%) were also common. At least 1 cardiovascular risk factor was present in 64.7% of SCD victims. In conclusion, most SCDs among victims < 50 years of age are due to CAD.

1 October 2014 in Heart Rhythm
Verified
Journal Article
Closed access
Juhani JunttilaJuhani Junttila
Juhani Junttila
JTJani T Tikkanen
Jani T Tikkanen
TKTuomas Kenttä
Tuomas Kenttä
OAOlli Anttonen
Olli Anttonen
AAAapo L Aro
Aapo L Aro
HHHeikki V Huikuri
Heikki V Huikuri